Works matching DE "PEMBROLIZUMAB"
Results: 1225
Adjuvant immunotherapy for high‐risk renal cell carcinoma—now or never?
- Published in:
- BJU International, 2025, v. 135, n. 2, p. 235, doi. 10.1111/bju.16584
- By:
- Publication type:
- Article
Clinical outcomes by baseline metastases in patients with renal cell carcinoma treated with lenvatinib plus pembrolizumab versus sunitinib: Post hoc analysis of the CLEAR trial.
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 7, p. 1326, doi. 10.1002/ijc.35288
- By:
- Publication type:
- Article
Current usage of pembrolizumab in triple negative breast cancer (TNBC).
- Published in:
- Expert Review of Anticancer Therapy, 2024, v. 24, n. 5, p. 253, doi. 10.1080/14737140.2024.2341729
- By:
- Publication type:
- Article
A phase 2 basket study of talabostat, a small‐molecule inhibitor of dipeptidyl peptidases, administered in combination with pembrolizumab in patients with advanced solid cancers.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 3, p. 1, doi. 10.1002/cncr.35728
- By:
- Publication type:
- Article
First person profile: Julie Brahmer, MD: Dr Brahmer's research paved the way for the first immunotherapy agent to receive US Food and Drug Administration approval for the treatment of lung cancer.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 2, p. 1, doi. 10.1002/cncr.35686
- By:
- Publication type:
- Article
Comparative Effectiveness of First‐Line Pembrolizumab vs. Chemotherapy in aNSCLC: A Norwegian Population‐Based Cohort Study.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 4, p. 1123, doi. 10.1002/cpt.3591
- By:
- Publication type:
- Article
The 21st International Congress of the Society for Melanoma Research.
- Published in:
- Pigment Cell & Melanoma Research, 2025, v. 38, n. 1, p. 1, doi. 10.1111/pcmr.13218
- Publication type:
- Article
A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 3, p. 572, doi. 10.1002/psp4.13297
- By:
- Publication type:
- Article
Lenvatinib plus pembrolizumab compared to carboplatin plus paclitaxel for carboplatin and paclitaxel pretreated, recurrent, or advanced endometrial cancer.
- Published in:
- BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-03989-0
- By:
- Publication type:
- Article
Pembrolizumab: The Nut Cracker.
- Published in:
- Indian Journal of Medical & Paediatric Oncology, 2021, v. 42, n. 3, p. 393, doi. 10.4103/ijmpo.ijmpo_37_20
- By:
- Publication type:
- Article
Pembrolizumab as an effective treatment for diffuse malignant peritoneal mesothelioma with long‑term survival: A case report and literature review.
- Published in:
- Oncology Letters, 2025, v. 29, n. 4, p. N.PAG, doi. 10.3892/ol.2025.14933
- By:
- Publication type:
- Article
Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer.
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35757
- By:
- Publication type:
- Article
Pembrolizumab with chemoradiotherapy followed by pembrolizumab for stage III–IVa cervical cancer: is the ENGOT‐cx11/GOG‐3047/KEYNOTE‐A18 trial practice changing?
- Published in:
- Cancer (0008543X), 2025, v. 131, n. 4, p. 1, doi. 10.1002/cncr.35749
- By:
- Publication type:
- Article
A Case of Rapidly Progressing Urothelial Carcinoma Arising After Living Donor Kidney Transplantation Treated with Chemotherapy and Immune Checkpoint Inhibitors.
- Published in:
- Yonago Acta Medica, 2025, v. 68, n. 1, p. 75, doi. 10.33160/yam.2025.02.009
- By:
- Publication type:
- Article
First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma.
- Published in:
- Current Oncology, 2025, v. 32, n. 2, p. 68, doi. 10.3390/curroncol32020068
- By:
- Publication type:
- Article
Haemorrhage-related adverse events profles of lenvatinib and pembrolizumab alone or in combination: a real-world pharmacovigilance study based on FAERS database.
- Published in:
- BMC Pharmacology & Toxicology, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s40360-025-00878-3
- By:
- Publication type:
- Article
Vibration properties of immune‐oncological drugs.
- Published in:
- Journal of Raman Spectroscopy, 2022, v. 53, n. 4, p. 715, doi. 10.1002/jrs.6297
- By:
- Publication type:
- Article
Incidence and risk factors of acute kidney injury, and its effect on mortality among Japanese patients receiving immune check point inhibitors: a single-center observational study.
- Published in:
- Clinical & Experimental Nephrology, 2021, v. 25, n. 5, p. 479, doi. 10.1007/s10157-020-02008-1
- By:
- Publication type:
- Article
Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Tumour-immune dynamics with an immune checkpoint inhibitor.
- Published in:
- Letters in Biomathematics, 2018, v. 5, p. S137, doi. 10.1080/23737867.2018.1440978
- By:
- Publication type:
- Article
American Association of Cancer Research Showcases Immunotherapy Advances.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2015, v. 107, n. 8, p. 4, doi. 10.1093/jnci/djv231
- By:
- Publication type:
- Article
PDQ (Physician Data Query).
- Published in:
- 2014
- Publication type:
- Abstract
Transient altered mental status and leptomeningeal enhancement associated with pembrolizumab: a case report.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Clinical and magnetic resonance imaging monitoring in progressive multifocal leukoencephalopathy treated with pembrolizumab: a case report.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Long Noncoding RNA Hotair Promotes the Progression and Immune Escape in Laryngeal Squamous Cell Carcinoma through MicroRNA-30a/GRP78/PD-L1 Axis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Pembrolizumab dramatically resolves choroidal metastatis from esophageal adenocarcinoma and restores vision: a case report.
- Published in:
- Oxford Medical Case Reports, 2021, v. 2021, n. 6, p. 1, doi. 10.1093/omcr/omab047
- By:
- Publication type:
- Article
Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 12, p. 3165, doi. 10.1007/s13555-023-01059-y
- By:
- Publication type:
- Article
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-72118-3
- By:
- Publication type:
- Article
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-72118-3
- By:
- Publication type:
- Article
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-70779-8
- By:
- Publication type:
- Article
PD-1/PD-L1 Inhibitors in Cervical Cancer.
- Published in:
- Frontiers in Pharmacology, 2019, p. N.PAG, doi. 10.3389/fphar.2019.00065
- By:
- Publication type:
- Article
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
- Published in:
- Frontiers in Oncology, 2020, p. 1, doi. 10.3389/fonc.2020.00268
- By:
- Publication type:
- Article
Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00091
- By:
- Publication type:
- Article
Pembrolizumab Induced Ocular Hypotony With Near Complete Vision Loss, Interstitial Pulmonary Fibrosis and Arthritis.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00944
- By:
- Publication type:
- Article
Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00835
- By:
- Publication type:
- Article
Pembrolizumab in a Patient With a Metastatic CASTLE Tumor of the Parotid.
- Published in:
- Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00734
- By:
- Publication type:
- Article
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00264
- By:
- Publication type:
- Article
Rescue of Immunotherapy-Refractory Metastatic Merkel Cell Carcinoma With Conventionally Fractionated Radiotherapy and Concurrent Pembrolizumab.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00223
- By:
- Publication type:
- Article
Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
<italic>In‐vitro</italic> effect of pembrolizumab on different T regulatory cell subsets.
- Published in:
- Clinical & Experimental Immunology, 2018, v. 191, n. 2, p. 189, doi. 10.1111/cei.13060
- By:
- Publication type:
- Article
Recurrent Sympathetic Ophthalmia with Annular Choroidal Detachment after Pembrolizumab Treatment: A Case Report.
- Published in:
- Ocular Immunology & Inflammation, 2020, v. 28, n. 6, p. 864, doi. 10.1080/09273948.2019.1604975
- By:
- Publication type:
- Article
Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer.
- Published in:
- Lung Cancer: Targets & Therapy, 2020, v. 11, p. 53, doi. 10.2147/LCTT.S254146
- By:
- Publication type:
- Article
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2017, v. 8, p. 1, doi. 10.2147/LCTT.S105678
- By:
- Publication type:
- Article
Targeting PD-I/PD-LI in lung cancer: current perspectives.
- Published in:
- Lung Cancer: Targets & Therapy, 2015, v. 6, p. 55, doi. 10.2147/LCTT.S55176
- By:
- Publication type:
- Article
Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor.
- Published in:
- Case Reports in Urology, 2020, p. 1, doi. 10.1155/2020/8881841
- By:
- Publication type:
- Article
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.
- Published in:
- PharmacoEconomics, 2024, v. 42, n. 6, p. 615, doi. 10.1007/s40273-024-01381-z
- By:
- Publication type:
- Article
Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
- Published in:
- PharmacoEconomics, 2022, v. 40, n. 12, p. 1247, doi. 10.1007/s40273-022-01196-w
- By:
- Publication type:
- Article
Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2019
- By:
- Publication type:
- journal article